Mechanistic Comparison# Dosing Comparison# Amycretin Dosing# Amycretin dosing is investigational: Subcutaneous: Once-weekly injection, doses up to 60 mg studied in phase 1b/2a over 36 weeks Oral: Daily tablet, doses up to 50 mg (or 2 x 50 mg) studied in phase 1 Phase 2 T2D: Both subcutaneous and oral formulations studied over 36 weeks Phase 3 dose selection will be informed by the completed phase 2 data
Through these routes, IGF-1 LR3 may promote the movement of glucose transporters to the cell surface, facilitating uptake into experimental cell systems
Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials
Scope and Incorporation This Research Use Only Disclaimer (RUO Disclaimer) applies to every product, page, communication, order, and shipment from BGX Performance